HURA - Earnings announcements

Company's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) targeting completion of enrollment Q4-2026 A mini KOL symposium held on December 5, 2025, provided the scientific rational for targeting VISTA in AML and the clinical applications in combination with a menin inhibitor in NPM1 mutated relapsed/refractory AML Oral and poster presentations at the recently concluded 57th ASH Annual Meeting showed the Delta Opioid Receptor (DOR) to be a compelling new target as th

Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda® (pembrolizumab) in 1st line therapy for advanced Merkel cell carcinoma (MCC) planning to initiate enrollment in Q2 2025 MCC Phase 3 trial to be conducted under Special Protocol Assessment (SPA) Agreement with FDA Acquisition of Kineta's Phase 2 ready, VISTA inhibiting antibody targeted for completion in Q2 2025 Expanded discovery team for first-in-class immune modulating Antibody Drug or Peptide Conjugate Program TAMPA, Fla., April 1, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overco